ReportsnReports

Market of Drugs for Progressive Dementia with Other Neurological Abnormalities Analyzed in New Research Report

"Global Markets for Treatments of Dementia and Movement Disorders -- Focus on Progressive Dementia with Other Neurological Abnormalities" explores present and future strategies within the neurodegenerative disorder market, which includes treatments and therapies for progressive dementia, progressive dementia with other neurological abnormalities and movement disorders.

 
Repost This

Dallas, TX -- (SBWIRE) -- 09/28/2012 -- The global sales of drugs to treat progressive dementia with other neurological abnormalities expected to reach $537.2 million in 2012 and $913.7 million by 2017, at a CAGR of 11.2% over the five-year forecast period. Sales of drugs to treat Huntington’s disease patients with progressive dementia and other neurological abnormalities expected to reach $354.4 million in 2012 and further increase to $566.8 million in 2017, at a CAGR of 9.8% over the five-year forecast period. The global market for treatments for syndromes of dementia and movement disorders was valued at 10.5 billion in 2011 and should reach $11.1 billion in 2012. Total market value is expected to reach $16.7 billion in 2017 after increasing at a five-year compound annual growth rate (CAGR) of 8.5%.

Extensive research in the field of syndromes of dementia and movement disorders and company collaborations with research institutes have highlighted the importance of understanding the nature of these disorders. New technological developments are providing disease-modifying therapies for the late stages of the disorders. Collaborations between research institutes and pharmaceutical companies are on the rise as state-of-the-art technology is being explored to develop more efficient products and therapies.

R&D spending, along with increasing competition, patent expiries and new technologies are taking the market in a new direction. Global market revenues increased from 2009 to 2011 and are expected to continue to show growth over the forecast period as new advances, launches and collaborations continue to influence the market. This study looks at most of the systems affected by these factors.

Acquisition strategies and collaborations by companies are also covered in this report. This study also discusses the strength and weaknesses of each type of technology in light of the new technologies, growing competition and changing customer needs.

This study contributes to the areas of market growth in treatments for Alzheimer’s disease, Lewy body dementia, Pick’s disease, Huntington’s disease, corticobasal ganglionic degeneration, Parkinson’s disease, multiple system atrophy, progressive supranuclear palsy and Hallervorden-Spatz disease. Pharmaceutical biotechnical companies, research institutes and physicians will find this study to be of interest.

Buy your copy of this report @ http://www.reportsnreports.com/reports/194887-global-markets-for-treatments-of-dementia-and-movement-disorders-focus-on-progressive-dementia-with-other-neurological-abnormalities.html.

Table Of Contents
Chapter- 1: Introduction
Study Objectives
Reasons For Doing This Study
Contributions Of The Study And For Whom
Scope Of The Study
Methodology
Information Sources
About The Author
Related Bcc Research Reports
Bcc Online Services
Disclaimer
Chapter- 2: Executive Summary
Table Summary : Global Market For Treatments For Syndromes Of Dementia And Movement Disorders, Through 2017
Figure Summary : Global Market For Treatments For Syndromes Of Dementia And Movement Disorders, 2010-2017
Chapter- 3: Overview
The Brain
Classification Of Neurodegenerative Disorders
Neurodegenerative Disorders
Diagnostic Tests For Neurodegenerative Disorders
Chapter- 4: Regulatory Aspects
Introduction
Drug Approvals
Regulatory Developments Affecting Syndromes Of Dementia And Movement Disorder Products
Chapter- 5: New Developments
Table 6 : New Developments In Drugs Used To Treat Syndromes Of Dementia And Movement Disorders, 2012
Table 7 : New Developments In Drugs Used To Treat Syndromes Of Dementia And Movement Disorders, 2011
Table 8 : New Developments In Drugs Used To Treat Syndromes Of Dementia And Movement Disorders, 2010
Chapter- 6: Global Markets
Markets By Clinical/Pathological Feature
Market By Disease Type
Market By Region
Markets By Technology
Chapter- 7: Market For Drugs To Treat Progressive Dementia With Other Neurological Abnormalities
Market By Disease Type
Market By Region
Regional Markets By Disease Type
Market By Technology
Industry Structure
Chapter- 8: Patent Analysis
Patents Issued By Year
Patents By Disease Category
Patents By Disease Type
Patents By Country
Patents By Company
Chapter- 9: Current Situation
Market Trends
Overall Drivers Of The Market For Treatments For Syndromes Of Dementia And Movement Disorders
Other Factors Affecting The Market
Collaborations/Mergers And Acquisitions
Chapter- 10: Company Profiles
Abbott Laboratories
Ablynx Nv
Accera Inc.
Acorda Therapeutics Inc.
Actavis Elizabeth
Affiris Ag
Alliance Pharma Plc
Allon Therapeutics Inc.
Alphapharm
Alzhyme Ltd.
American Regent Inc.
Apotex Inc.
Apotheca Inc.
Astellas Pharma Inc.
Astrazeneca Gmbh
Aurobindo Pharma Ltd.
Baxter International Inc.
Bellus Health Inc.
Boehringer Ingelheim Ltd.
Bristol-Myers Squibb
Bryant Ranch Prepack
Cadila Healthcare Ltd.
Caraco Pharmaceutical Laboratories
Cardinal Health
Cellzome Ag
Cipla Ltd.
Cognition Therapeutics Inc.
Colucid Pharmaceuticals Inc.
Comentis Inc.
Cortex Pharmaceuticals
Cytos Biotechnology Ag
Daiichi Sankyo Co. Ltd.
Dr. Reddy's Laboratories Ltd.
Eisai Co. Ltd.
Elan Pharma International Ltd.
Eli Lilly And Co.
Endo Pharmaceuticals Inc.
Envivo Pharmaceuticals
Evotec Ag
Epitomics Inc.
Exonhit Therapeutics Sa
Forest Laboratories Inc.
Glaxosmithkline Plc
Glenmark Generics Ltd.
H. Lundbeck A/S
Hameln Pharmaceuticals Ltd.
Helicon Therapeutics Inc.
Hospira Inc.
Intellect Neurosciences Inc.
Intra-Cellular Therapies Inc.
Jazz Pharmaceuticals Plc
Major Pharmaceuticals
Medivation Inc.
Memory Pharmaceuticals Corp.
Merck Serono
Merck Sharp & Dohme Ltd.
Merz Pharma Gmbh & Co Kgaa
Mithridion Inc.
Mylan Pharmaceuticals
Neuren Pharmaceuticals Ltd.
Neuro-Hitech Inc.
Neuroptix Corp.
Neurosearch A/S
Newron Pharmaceuticals Spa
Noscira Sa
Novartis Ag
Nymox Pharmaceutical Corp.
Orchid Chemicals & Pharmaceuticals Ltd.
Orion Corp.
Ortho-Mcneil Janssen Pharmaceuticals Inc.
Par Pharmaceuticals
Perrigo Co.
Pfizer Inc.
Pharnext
Physicians Total Care Inc.
Pliva Hrvatska D.O.O.
Prasco Laboratories
Ranbaxy Laboratories Ltd.
Roche Holding Ltd.
Roxane Laboratories Inc.
Sandoz International Gmbh
Sanofi
Santhera Pharmaceuticals
Shionogi & Co.
Stada Arzneimittel Ag
Sun Pharma
Taj Pharmaceuticals Ltd.
Takeda Pharmaceutical Co. Ltd.
Tercica Inc.
Teva Pharmaceutical Industries Ltd.
Torrent Pharma
Ucb Sa
Udl Laboratories
Upsher-Smith Laboratories
Valeant Pharmaceuticals
Vernalis Plc
Watson Pharmaceuticals Inc.
West-Ward Pharmaceutical
Chapter- 11: Appendix I: Abbreviations
List Of Tables
Summary Table : Global Market For Treatments For Syndromes Of Dementia And Movement Disorders, Through 2017
Table 1 : Classification Of Syndromes Of Dementia And Movement Disorders By Primary Clinical/Pathological Feature
Table 2 : Anda And Nda Approvals Of Drugs Used To Treat Syndromes Of Dementia And Movement Disorders, 2010 To March 2012
Table 3 : Pending New Drug Applications For Drugs Used To Treat Syndromes Of Dementia And Movement Disorders
Table 4 : Fda Drug Safety Alerts, 2010 To March 2012
Table 5 : Fda Recalls Of Drugs Used To Treat Syndromes Of Dementia And Movement Disorders, 2010 To March 2012
Table 6 : New Developments In Drugs Used To Treat Syndromes Of Dementia And Movement Disorders, 2012
Table 7 : New Developments In Drugs Used To Treat Syndromes Of Dementia And Movement Disorders, 2011
Table 8 : New Developments In Drugs Used To Treat Syndromes Of Dementia And Movement Disorders, 2010
Table 9 : Global Sales Of Drug Products Used To Treat Syndromes Of Dementia And Movement Disorders, Through 2017
Table 10 : Global Market Shares Of Drug Products Used To Treat Neurodegenerative Disorders By Clinical/Pathological Feature, 2011
Table 11 : Global Sales Of Drug Products Used To Treat Major Neurodegenerative Disorders, Through 2017
Table 12 : Global Market Shares Of Drug Products Used To Treat Syndromes Of Dementia And Movement Disorders By Disease Type, 2011
Table 13 : Global Sales Of Drug Products Used To Treat Syndromes Of Dementia And Movement Disorders By Region, Through 2017
Table 14 : Global Market Shares Of Drug Products Used To Treat Syndromes Of Dementia And Movement Disorders By Region, 2011
Table 15 : Global Sales Of Drug Products Used To Treat Syndromes Of Dementia And Movement Disorders By Technology, Through 2017
Table 16 : Global Market Shares Of Drug Products Used To Treat Syndromes Of Dementia And Movement Disorders By Technology, 2011
Table 17 : Chdi Foundations’ Key Developments In Treating Huntington’s Disease
Table 18 : Global Sales Of Drug Products Used To Treat Progressive Dementia With Other Neurological Abnormalities By Type Of Disease, Through 2017
Table 19 : Global Market Shares Of Drug Products Used To Treat Progressive Dementia With Other Neurological Abnormalities By Disease Type, 2011
Table 20 : Global Sales Of Drug Products Used To Treat Progressive Dementia With Other Neurological Abnormalities By Region, Through 2017
Table 21 : Global Market Shares Of Drug Products Used To Treat Progressive Dementia With Other Neurological Abnormalities By Region, 2011
Table 22 : Global Sales Of Drug Products Used To Treat Huntington’s Disease By Region, Through 2017
Table 23 : Global Sales Of Drugs Used To Treat Corticobasal Ganglionic Degeneration By Region, Through 2017
Table 24 : Global Sales Of Drug Products Used To Treat Progressive Dementia With Other Neurological Abnormalities By Technology, Through 2017
Table 25 : Global Market Shares Of Drug Products Used To Treat Progressive Dementia With Other Neurological Abnormalities By Technology, 2011
Table 26 : Leading Manufacturers/Suppliers Of Drugs/Therapies Used To Treat Huntington’s Disease
Table 27 : Manufacturer/Distributor Market Shares Of Drug Products Used To Treat Huntington’s Disease, 2011
Table 28 : Leading Manufacturers/Suppliers Of Drugs/Therapies Used To Treat Huntington’s Disease
Table 29 : Manufacturer/Distributor Market Shares Of Drug Products Used To Treat Corticobasal Ganglionic Degeneration, 2011
Table 30 : U.S. Patents On Drugs Used To Treat Syndromes Of Dementia And Movement Disorders Issued Per Year, 2010-March 2012
Table 31 : U.S. Patents On Drugs Used To Treat Syndromes Of Dementia And Movement Disorders By Category Of Disease, 2010-March 2012
Table 32 : U.S. Patents On Drugs Used To Treat Syndromes Of Dementia (Progressive Dementia) By Clinical/Pathological Feature, 2010-March 2012
Table 33 : U.S. Patents On Drugs Used To Treat Movement Disorder Syndromes By Disease Type, 2010-March 2012
Table 34 : U.S. Patents On Drugs Used To Treat Syndromes Of Dementia (Progressive Dementia) By Patent Holder’s Country, 2010-March 2012
Table 35 : U.S. Patent Shares Of Drugs Used To Treat Progressive Dementia By Patent Holder’s Country, 2010-March 2012
Table 36 : U.S. Patents On Drugs Used To Treat Movement Disorder Syndromes By Patent Holder’s Country, 2010-March 2012
Table 37 : U.S. Patent Shares Of Drugs Used To Treat Movement Disorder Syndromes By Patent Holder’s Country, 2010-March 2012
Table 38 : Number Of U.S. Patents On Drugs Used To Treat Syndromes Of Dementia (Progressive Dementia) By Company, 2010-March 2012
Table 39 : U.S. Patents On Drugs Used To Treat Movement Disorder Syndromes By Company, 2010-March 2012
List Of Figures
Summary Figure : Global Market For Treatments For Syndromes Of Dementia And Movement Disorders, 2010-2017
Figure 1 : Global Sales Of Drug Products Used To Treat Syndromes Of Dementia And Movement Disorders, 2010-2017
Figure 2 : Global Market Shares Of Drug Products Used To Treat Neurodegenerative Disorders By Clinical/Pathological Feature, 2011
Figure 3 : Global Sales Of Drug Products Used To Treat Major Neurodegenerative Disorders, 2010-2017
Figure 4 : Global Market Shares Of Drug Products Used To Treat Syndromes Of Dementia And Movement Disorders By Disease, 2011
Figure 5 : Global Sales Of Drug Products Used To Treat Syndromes Of Dementia And Movement Disorders By Region, 2010-2017
Figure 6 : Global Market Shares Of Drug Products Used To Treat Syndromes Of Dementia And Movement Disorders By Region, 2011
Figure 7 : Global Sales Of Drug Products Used To Treat Syndromes Of Dementia And Movement Disorders By Technology, 2010-2017
Figure 8 : Global Market Shares Of Drug Products Used To Treat Syndromes Of Dementia And Movement Disorders By Technology, 2011
Figure 9 : Global Sales Of Drug Products Used To Treat Progressive Dementia With Other Neurological Abnormalities By Type Of Disease, 2010-2017
Figure 10 : Global Market Shares Of Drug Products Used To Treat Progressive Dementia With Other Neurological Abnormalities By Disease Type, 2011
Figure 11 : Global Sales Of Drug Products Used To Treat Progressive Dementia With Other Neurological Abnormalities By Region, 2010-2017
Figure 12 : Global Market Shares Of Drug Products Used To Treat Progressive Dementia With Other Neurological Abnormalities By Region, 2011
Figure 13 : Global Sales Of Drugs Used To Treat Huntington’s Disease By Region, 2010-2017
Figure 14 : Global Sales Of Drugs Used To Treat Corticobasal Ganglionic Degeneration By Region, Through 2017
Figure 15 : Global Sales Of Drug Products Used To Treat Progressive Dementia With Other Neurological Abnormalities By Technology, 2010-2017
Figure 16 : Global Market Shares Of Drug Products Used To Treat Progressive Dementia With Other Neurological Abnormalities By Technology, 2011
Figure 17 : Manufacturer/Distributor Market Shares Of Drug Products For Used To Treat Huntington’s Disease, 2011
Figure 18 : Manufacturer/Distributor Market Shares Of Drugs Used To Treat Corticobasal Ganglionic Degeneration, 2011
Figure 19 : U.S. Patents On Drugs Used To Treat Syndromes Of Dementia And Movement Disorders Issued Per Year, 2010—March 2012
Figure 20 : Percentage Of U.S. Patents On Drugs Used To Treat Syndromes Of Dementia And Movement Disorders Issued Per Year, 2010-March 2012
Figure 21 : U.S. Patents On Drugs Used To Treat Syndromes Of Dementia And Movement Disorders By Category Of Disease, 2010-March 2012
Figure 22 : U.S. Patents On Drugs Used To Treat Syndromes Of Dementia By Clinical/Pathological Feature, 2010-March 2012*
Figure 23 : U.S. Patents On Drugs Used To Treat Movement Disorder Syndromes By Disease Type, 2010-March 2012
Figure 24 : U.S. Patents On Drugs Used To Treat Syndromes Of Dementia (Progressive Dementia) By Patent Holder’s Country, 2010-March 2012
Figure 25 : U.S. Patents On Drugs Used To Treat Movement Disorder Syndromes By Patent Holder’s Country, 2010-March 2012

Contact sales@reportsandreports.com for further information.